Pesquisar
Edap Tms SA
EDAPAdicionar à lista de desejos
4.320USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
194.17MValor de mercado
PerdaP/L TTM
Mais detalhes de Edap Tms SA Empresa
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
Informações de Edap Tms SA
Código da empresaEDAP
Nome da EmpresaEdap Tms SA
Data de listagemAug 01, 1997
CEORhodes (Ryan)
Número de funcionários310
Tipo de títulosDepository Receipt
Fim do ano fiscalAug 01
Endereço4, rue du Dauphine
CidadeVAULX-EN-VELIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal69120
Telefone33472153150
Sitehttps://focalone.com/fr/accueil/
Código da empresaEDAP
Data de listagemAug 01, 1997
CEORhodes (Ryan)
Executivos da empresa Edap Tms SA
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lance Willsey
Dr. Lance Willsey
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
1.24M
-7.52%
Mr. Ryan Rhodes
Mr. Ryan Rhodes
Chief Executive Officer, Director, Chief Executive Officer of EDAP Technomed Inc
Chief Executive Officer, Director, Chief Executive Officer of EDAP Technomed Inc
637.83K
+47.74%
Mr. Joshua H. (Josh) Levine
Mr. Joshua H. (Josh) Levine
Independent Director
Independent Director
25.00K
--
Ms. Fran Schulz
Ms. Fran Schulz
Independent Director
Independent Director
5.10K
--
Herve De Soultrait
Herve De Soultrait
General Manager of EDAP Technomed (M) Sdn, Bhd
General Manager of EDAP Technomed (M) Sdn, Bhd
--
--
Mr. Jean-Francois Bachelard
Mr. Jean-Francois Bachelard
President and Chief Executive Officer of Edap Technomed Co Ltd (Japan)
President and Chief Executive Officer of Edap Technomed Co Ltd (Japan)
--
--
Ms. Blandine Confort
Ms. Blandine Confort
Investor Relations Officer, Director - Legal Affairs
Investor Relations Officer, Director - Legal Affairs
--
--
Mr. Francois Dietsch
Mr. Francois Dietsch
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Ken Mobeck
Mr. Ken Mobeck
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Glen French
Mr. Glen French
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lance Willsey
Dr. Lance Willsey
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
1.24M
-7.52%
Mr. Ryan Rhodes
Mr. Ryan Rhodes
Chief Executive Officer, Director, Chief Executive Officer of EDAP Technomed Inc
Chief Executive Officer, Director, Chief Executive Officer of EDAP Technomed Inc
637.83K
+47.74%
Mr. Joshua H. (Josh) Levine
Mr. Joshua H. (Josh) Levine
Independent Director
Independent Director
25.00K
--
Ms. Fran Schulz
Ms. Fran Schulz
Independent Director
Independent Director
5.10K
--
Herve De Soultrait
Herve De Soultrait
General Manager of EDAP Technomed (M) Sdn, Bhd
General Manager of EDAP Technomed (M) Sdn, Bhd
--
--
Mr. Jean-Francois Bachelard
Mr. Jean-Francois Bachelard
President and Chief Executive Officer of Edap Technomed Co Ltd (Japan)
President and Chief Executive Officer of Edap Technomed Co Ltd (Japan)
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Edap Tms SA?
Os cinco principais acionistas de Edap Tms SA são: Dr. Lance Willsey
Quantas instituições possuem ações da Edap Tms SA (EDAP)?
Em 2026Q1, 70 instituições possuíam ações da Edap Tms SA, com valor de mercado aproximado de 14.62M, representando 39.01% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -711403.00.